TD Private Client Wealth’s Cellebrite CLBT Stock Holding History

TD Private Client Wealth’s Portfolio CLBT Stock Details CLBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-629	Closed	-$12.2K	–	1430
2025 Q1	$12.2K	Buy	+629	New	+$13.2K	﹤0.01%	993

Other funds holding CLBT

TWCM

True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return

Axon Enterprise Scottsdale, Arizona $19.1M AUM 8.75% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TD Private Client Wealth's CLBT Position: Q2 2025 in Review

TD Private Client Wealth sold out of Cellebrite (CLBT) in Q2 2025, closing a stake of 629 shares — an estimated $12.2K sold.

TD Private Client Wealth first reported a position in CLBT in Q1 2025 and held it in 1 quarter. The position peaked at $12.2K in Q1 2025. 209 funds tracked by Wall St. Rank hold CLBT as of Q2 2025.

TD Private Client Wealth reported no remaining Cellebrite position as of Q2 2025 after selling out during the quarter.
TD Private Client Wealth sold 629 Cellebrite shares in Q2 2025, an estimated $12.2K.
TD Private Client Wealth first reported a position in Cellebrite in Q1 2025 and held it in 1 quarter.
TD Private Client Wealth's Cellebrite position peaked at $12.2K in Q1 2025.
209 funds tracked by Wall St. Rank held Cellebrite as of Q2 2025.

Based on TD Private Client Wealth's 13F filing for Q2 2025, filed 15 Jul 2025.